NIH researchers know in 2026 that shingles vaccination is linked to a potentially meaningful reduction in dementia risk, but they do not yet know that it prevents dementia. The evidence comes mainly from observational studies and natural experiments, not definitive randomized clinical trials. Shingrix is FDA-approved and CDC-recommended to prevent shingles and related complications—not dementia. For example, a 2025 study in Wales found fewer dementia diagnoses among people eligible for an older shingles vaccine, but that study examined Zostavax rather than today’s non-live Shingrix vaccine.
The signal is strong enough that the National Institute on Aging, the National Institute of Allergy and Infectious Diseases, and the National Institute of Neurological Disorders and Stroke jointly organized a June 1–2, 2026 workshop titled “Zoster Vaccine and Dementia Risk Reduction: Evidence and Mechanisms.” The meeting was designed to identify research gaps, possible biological mechanisms, useful datasets, and considerations for clinical-efficacy studies. It was a research workshop, not an NIH recommendation to use shingles vaccination as dementia prevention. For patients and families, the distinction matters. An adult may have a clear, evidence-based reason to receive Shingrix because it substantially protects against shingles and its complications. Any possible dementia benefit should currently be viewed as encouraging but unconfirmed additional evidence, not as a promised outcome or a substitute for established medical care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Do NIH Researchers Know About Shingles Vaccination and Dementia Risk in 2026?
- What the Wales Zostavax Study Actually Found
- What Studies of Shingrix Show
- Who Should Receive Shingrix and on What Schedule?
- Why Shingrix and Zostavax Cannot Be Treated as Interchangeable Evidence
- How Dementia Diagnosis Can Affect the Research Results
- What to Discuss With a Clinician Before Vaccination
- Frequently Asked Questions
What Do NIH Researchers Know About Shingles Vaccination and Dementia Risk in 2026?
NIH’s interest reflects a growing pattern across several types of research. Studies using health records, insurance claims, and vaccine-eligibility rules have repeatedly found lower rates or delayed diagnoses of dementia among shingles-vaccinated groups. Different datasets pointing in a similar direction make the question scientifically important, but repeated associations do not automatically establish cause and effect. The National Institute on Aging's May 2026 workshop announcement shows how NIH is approaching the subject: investigators are examining mechanisms, data quality, and the design of future efficacy studies.
This is a more cautious position than a prevention guideline. NIH’s public-facing information still says more research is needed, and neither NIH nor CDC advises people to receive Shingrix specifically to prevent dementia. A useful comparison is the difference between a promising cardiovascular biomarker and a proven heart-disease treatment. A consistent biomarker may justify major research investment, but doctors generally need controlled evidence showing that changing it improves patient outcomes. In the same way, the vaccine-dementia association is compelling enough to study rigorously without yet qualifying as a proven dementia intervention.
What the Wales Zostavax Study Actually Found
The strongest causal-style evidence so far came from a 2025 Nature study that used a vaccine-eligibility cutoff in Wales. People born just before a particular date were eligible for the older live shingles vaccine, Zostavax, while people born just after it were not. Because people on either side of a narrow birth-date cutoff tend to be otherwise similar, the design reduced some of the “healthy vaccinee” bias that affects ordinary comparisons between people who choose vaccination and those who do not. Investigators estimated that vaccination reduced the probability of a new dementia diagnosis by 3.5 percentage points over seven years, corresponding to a 20.0% relative reduction. The reported 95% confidence interval for the relative reduction was 6.5% to 33.4%, with P=.019.
The absolute and relative figures describe the same result from different angles: 3.5 percentage points refers to the difference in diagnosed cases across the studied populations, while 20.0% describes that difference relative to the baseline probability. There are two important limitations. The study was a natural experiment, not a randomized controlled trial, and it evaluated Zostavax, a live-virus vaccine that is no longer used in the United States. It therefore cannot establish that Shingrix produces the same effect. Eligibility also does not guarantee that every eligible person was vaccinated, and dementia diagnoses recorded in routine health systems may not capture every case or the precise date when disease began.
What Studies of Shingrix Show
Shingrix has also been associated with lower dementia risk. A 2024 Nature Medicine study used U.S. electronic health records to compare matched cohorts vaccinated around the 2017 transition from the older live vaccine to the recombinant vaccine. Shingrix recipients had 17% more time without a dementia diagnosis during six years of follow-up. Among participants who were later diagnosed, that translated to 164 additional dementia-diagnosis-free days.
That result does not mean Shingrix delayed dementia by exactly 164 days for every vaccinated person. It is a group-level estimate among people who eventually received a diagnosis, and diagnosis-free time may be affected by healthcare use, documentation, screening practices, and other differences that matching cannot fully remove. The authors explicitly stated that the observational design could not demonstrate causality. A 2025 study in the journal Vaccine examined Optum insurance claims from 2017 through 2022 and likewise found lower subsequent dementia risk among recombinant zoster vaccine recipients. The investigators described Shingrix’s effectiveness for dementia prevention as uncertain because the work was a retrospective cohort study. For example, people who complete a two-dose vaccine series may also be more likely to attend preventive visits, manage blood pressure, or receive earlier cognitive assessment—behaviors that can complicate comparisons even after statistical adjustment.
Who Should Receive Shingrix and on What Schedule?
CDC recommends two Shingrix doses for immunocompetent adults age 50 and older, generally separated by two to six months. It also recommends two doses for adults age 19 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. In some immunocompromised patients, the second dose may be given one to two months after the first when faster completion would be beneficial. A prior episode of shingles does not remove eligibility, and neither does previous receipt of Zostavax.
For example, a 68-year-old who received Zostavax years ago may still be advised to complete the Shingrix series. A 42-year-old receiving strongly immunosuppressive treatment may also qualify, while a healthy 42-year-old generally does not fall within the routine CDC recommendation. The practical tradeoff is clearer for shingles prevention than for dementia prevention. Shingrix has an established indication and vaccination schedule for preventing shingles and related complications, while a cognitive benefit remains under study. Patients should discuss timing with a clinician, particularly during an acute illness, after a recent shingles episode, or around immunosuppressive treatment, rather than changing the schedule in hopes of obtaining an unproven neurological effect.
Why Shingrix and Zostavax Cannot Be Treated as Interchangeable Evidence
Shingrix is a recombinant, adjuvanted vaccine, formally named “Zoster Vaccine Recombinant, Adjuvanted.” It contains varicella-zoster-virus glycoprotein E and the AS01 adjuvant system; it does not contain live virus. FDA initially approved it in the United States in 2017, and the manufacturer is GSK. Zostavax, by comparison, was a live attenuated vaccine. That formulation difference may matter when researchers ask why vaccination could be connected to dementia risk. A benefit might arise from preventing varicella-zoster reactivation, reducing inflammation associated with shingles, stimulating broader immune responses, or some combination of pathways.
Different vaccine technologies could influence those processes differently. The Wales findings therefore cannot simply be transferred to Shingrix, even though U.S. observational studies of Shingrix point in a similar direction. A warning is especially important here: the current FDA indication for Shingrix covers prevention of herpes zoster in adults 50 and older and in adults 18 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. It does not include dementia prevention. The label revised in February 2026 also states that Shingrix is not indicated to prevent primary varicella, commonly called chickenpox.
How Dementia Diagnosis Can Affect the Research Results
Dementia develops over years, while a recorded diagnosis reflects a particular encounter within a healthcare system. A study may therefore measure the timing of documentation rather than the biological onset of disease. If one group receives more routine care, its members might be evaluated sooner; if another group has disrupted care, diagnoses might appear later even without a true difference in brain health.
Consider two adults with comparable early cognitive changes. One attends regular preventive appointments and receives cognitive testing promptly, while the other seeks care only after symptoms interfere with daily life. Their medical records will show different diagnosis dates even if their underlying disease began at roughly the same time. Researchers can adjust for measured differences, but electronic records and claims data rarely capture education, social support, health behavior, frailty, and access to specialist evaluation with equal precision.
What to Discuss With a Clinician Before Vaccination
A useful clinical conversation should begin with established eligibility: age, immune status, previous shingles, earlier Zostavax vaccination, current illness, and the timing of immune-suppressing treatment. Patients can also ask how to plan for the second dose and what short-term reactions might affect work, caregiving, or other responsibilities.
Dementia concerns may be part of the discussion, but they should not be represented as an approved indication. For example, a family caregiver arranging vaccination for a 72-year-old parent with mild cognitive impairment should tell the clinician about medications, immune conditions, and any previous vaccine reactions. The parent’s cognitive diagnosis does not make Shingrix a dementia treatment, but age alone places that person within CDC’s routine two-dose recommendation for shingles prevention.
Frequently Asked Questions
Is Shingrix approved to prevent dementia?
No. FDA approves Shingrix to prevent shingles in adults 50 and older and in adults 18 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. Dementia prevention is not an approved indication.
Does CDC recommend Shingrix for brain health?
CDC recommends Shingrix according to age and immune status to prevent shingles and related complications. It does not currently recommend the vaccine as a dementia-prevention intervention.
Did a study find a 20% reduction in dementia?
The 2025 Wales natural experiment estimated a 20.0% relative reduction in new dementia diagnoses over seven years, equivalent to a 3.5-percentage-point absolute reduction. It studied the older live vaccine, Zostavax, and was not a randomized trial.
Has Shingrix itself been studied?
Yes. U.S. electronic-health-record and insurance-claims studies have associated Shingrix with lower dementia risk or more diagnosis-free time. Because these were observational studies, they cannot prove that vaccination caused the difference.
Can someone who already had shingles or Zostavax receive Shingrix?
Yes. Prior shingles or previous Zostavax vaccination does not remove eligibility under CDC recommendations. A clinician can advise on appropriate timing.
